ABOUT US
Thrombotic Microangiopathy represents a broad range of diseases
The term thrombotic microangiopathy or TMA represents a broad pathophysiologic process that leads to the development of a microangiopathic hemolytic anemia (MAHA)
-
RESEARCH FACILITIES AND RESOURCES
The MAHA is a result of a micro thrombotic disease that involves the arterioles and capillaries of vascular beds throughout the body. These widespread microthrombi are the cause of the widespread and varied end organ injury that can be seen in patients diagnosed with a TMA. The term TMA is also an umbrella term that encompasses many conditions that can present with the characteristic MAHA and thrombocytopenia, but with differing and distinct pathophysiologies and treatment approaches.
OUR BOARD FOR THE CONSORTIUM
Led by Passionate Experts
Marshall Mazepa, MD
University of Minnesota
Spero R Cataland, MD
Ohio State University
University of Colorado
Shruti Chaturvedi, M.B.B.S., MS
Johns Hopkins University
Children's Healthcare of Atlanta
